ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,070.55
1.20%
US Tech 100
17,113.20
0.65%
Dow Jones
38,503.69
0.00%
Brent Oil
87.325
-0.27%
Bitcoin
66,534.93
0.19%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aligos Therapeutics Inc (ALGS) Quote

Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

NASDAQ
0.8236
0.0226
(2.82%)
Closed April 23 4:00PM
Delayed by 15 minutes
0.8236
0.00
( 0.00% )
Pre Market: 7:34AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.8236
Bid
0.782
Ask
0.889
Volume
-
0.00 Day's Range 0.00
0.5388 52 Week Range 1.38
Market Cap
62.048M
Previous Close
0.8236
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
406,060
Shares Outstanding
75,668,521
Dividend Yield
-
PE Ratio
-0.71
Earnings Per Share (EPS)
-1.16
Revenue
15.53M
Net Profit
-87.68M

About Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.aligos.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALGS. The last closing price for Aligos Therapeutics was $0.82. Over the last year, Aligos Therapeutics shares have traded in a share price range of $ 0.5388 to $ 1.38.

Aligos Therapeutics currently has 75,668,521 shares outstanding. The market capitalization of Aligos Therapeutics is $62.05 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.71.

ALGS Latest News

More News

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

April 09 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

April 03 2024
GlobeNewswire Inc.

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

March 27 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Screening of subjects has begun at clinical study sitesThe Phase 2a study is being led by Principal Investigator, Dr. Stephen HarrisonAligos anticipates dosing the first subject in Q2 2024 with...

March 18 2024
GlobeNewswire Inc.

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

March 12 2024
GlobeNewswire Inc.

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...

March 05 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 28 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 28 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01261.553637484590.8110.89770.732143690.79292897CS
4-0.1764-17.6411.10.733278350.95539733CS
120.153622.92537313430.671.20.624060600.89486447CS
260.223637.26666666670.61.20.53883436880.78735909CS
52-0.2064-20.03883495151.031.380.53882418700.87302125CS
156-23.8564-96.662884927124.6834.310.53882564424.54459243CS
260-13.9164-94.412483039314.7437.50990.53882388026.03714057CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2903
(90.61%)
15.94M
AMSTAmesite Inc
$ 3.04
(52.00%)
581.59k
RILYB Riley Financial Inc
$ 27.83
(28.13%)
147.15k
IMCCIM Cannabis Corporation
$ 0.7268
(27.44%)
7
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.71
(24.49%)
3.55M
EVOEvotec SE
$ 5.20
(-32.03%)
133.36k
TSDDGraniteShares ETF Trust GraniteShares
$ 26.68
(-24.85%)
22.54k
ESCAEscalade Inc
$ 10.35
(-24.78%)
11
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 42.50
(-24.00%)
298.5k
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 3.03
(-19.41%)
22
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.289
(89.76%)
15.94M
CYNCYNGN Inc
$ 0.1148
(0.70%)
7.64M
ZPTAZapata Computing Holdings Inc
$ 1.91
(22.44%)
5.41M
PEGYPineapple Energy Inc
$ 0.0564
(-0.35%)
4.97M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.71
(24.49%)
3.55M

ALGS Discussion

View Posts
BurgerKing82 BurgerKing82 2 months ago
Is March 7 a significant catalyst to get in by?
👍️0
TheFinalCD TheFinalCD 5 months ago
$ALGS PHASE 1 NEWS https://finviz.com/quote.ashx?t=ALGS&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/ALGS?a=dbb88c
👍️0
DewDiligence DewDiligence 6 months ago
ALGS 3Q23 results:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500015.html

No CC.
👍️0
DewDiligence DewDiligence 6 months ago
ALGS -15% on warrant-laden $92M financing:

https://www.globenewswire.com/news-release/2023/10/23/2764690/0/en/Aligos-Therapeutics-Announces-92-Million-Private-Placement-Financing.html
👍️0
DewDiligence DewDiligence 7 months ago
ALGS receives $8.5M NIAID grant for clinical development of ALG-097558:

https://finance.yahoo.com/news/aligos-therapeutics-announces-award-8-113000446.html

$8.5M won’t go very far, but I suppose that every little bit helps. ALGS is expected to report data from the phase-1 trial of ALG-097558 in 1H24.
👍️0
Monksdream Monksdream 7 months ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 7 months ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 7 months ago
ALG-055009 phase-2a in NASH expected_to_start 1Q24:

https://finance.yahoo.com/news/aligos-therapeutics-announces-ind-clearance-113000003.html

ALG-055009 is a thyroid hormone receptor beta agonist.
👍️0
Monksdream Monksdream 7 months ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 9 months ago
ALGS, JNJ reach agreement in principle to settle pending litigation:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001799448/000119312523200617/d538755d8k.htm

The terms will presumably be disclosed when the settlement in finalized.
👍️0
DewDiligence DewDiligence 9 months ago
The relatively low cash burn in 2Q23 was due to ALGS’ slashing R&D expenses by more than half relative to 2Q22 ($17M in 2Q23 vs 2Q22 $35M).
👍️0
DewDiligence DewDiligence 9 months ago
ALGS 2Q23 results—6/30/23 cash=$91M—(down $15M from 3/31/23):

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500975.html

Data from the phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, are expected in 1H24. The trial, which is being conducted in the UK, is currently in the SAD phase.

No CC.
👍️0
DewDiligence DewDiligence 10 months ago
ALGS HBV data at EASL:

https://www.globenewswire.com/news-release/2023/06/21/2692513/0/en/Aligos-Therapeutics-Presents-Data-from-its-Liver-Disease-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html
👍️0
DewDiligence DewDiligence 11 months ago
ALGS +51%/AH on collaboration with Chinese company:

https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Before the AH pop, ALGS’ enterprise value was deeply negative; after the AH pop, the EV is still negative but less so.

The up-front cash amount is presumably tiny since it wasn’t disclosed.

*Xiamen Amoytop Biotech Company Ltd.
👍️0
DewDiligence DewDiligence 12 months ago
ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

No CC.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS 4Q22 results—12/31/22 cash=$126M—4Q22 cash_burn=$16M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-210500130.html

ALGS’ COVID protease inhibitor, ALG-097558, is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS “de-prioritizes” HBV program—reduces workforce 10%:

https://finance.yahoo.com/news/aligos-therapeutics-announces-strategic-reprioritization-210500405.html Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck…

Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%...

…As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. In other words, the HBV program is getting the axe. After completing the early-stage HBV trials in progress, ALGS will offload these assets (if anyone wants them) or simply shut down the program.

The stock is flattish in the AH session.
👍️0
Laster Laster 1 year ago
Might hit $3 today.
Easily moving to $5.
Discussed this on HEPA board at under $1 in December.
Wow.
Yippee.
👍️0
Laster Laster 1 year ago
Beautiful. Will pass $2 today.
Best NASH play out there.
Good luck.
👍️0
Laster Laster 1 year ago
It’s running.
Amazing NASH stock.
$1.20.
$3 in February.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS provides 2023 roadmap:

https://www.globenewswire.com/news-release/2023/01/05/2583624/0/en/Aligos-Therapeutics-on-Track-to-Complete-Phase-2-Enabling-Activities-in-2023-for-its-Clinically-Validated-THR-%C3%9F-Drug-Candidate-for-NASH-ALG-055009.html
👍️0
DewDiligence DewDiligence 1 year ago
ALGS 3Q22 results—9/30/22 cash=$142M—3Q22 cash_burn=$17M:

https://www.globenewswire.com/news-release/2022/11/02/2547039/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2022-Financial-Results.html

ALGS’ COVID protease inhibitor, ALG-097558 is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 2Q22 results—6/30/22 cash=$159.3M—(down from $183M @3/31/22):

https://www.globenewswire.com/news-release/2022/08/04/2492772/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2022-Financial-Results.html

Phase-1 for the SARS-CoV-2 protease inhibitor, ALG-097558 has been delayed and is now expected to start in 2023, following a CTA filing in 1Q23. (The prior guidance was for an IND filing in 2H22.)
👍️0
DewDiligence DewDiligence 2 years ago
ALGS—Cash @3/31/22=$183M—$23B burn in 1Q22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500766.html

Other than the financials, there is no new news. ALGS still plans to start phase-1 for its COVID protease inhibitor in late 2022 or early 2023 (i.e. IND filing in 2H22).

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS selects lead SARS-CoV-2 PI—phase-1 expected to start in early 2023 (or very late 2022):

https://finance.yahoo.com/news/aligos-therapeutics-selects-drug-candidate-120000412.html

The timing of this program was known from the Leerink webcast two months ago (#msg-167924816), so the only new news is that a lead compound has been selected.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS discontinues another HBV candidate:

https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 4Q21 financials—12/31/21_cash=$205.8M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-fourth-quarter-210500703.html

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
Disclosure: I'm long ENTA.
👍️0
DewDiligence DewDiligence 2 years ago
Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.
👍️0
DewDiligence DewDiligence 2 years ago
Preclinical data on ALGS-097111 protease inhibitor from 2021 CROI:

https://www.aligos.com/wp-content/uploads/2021/03/CROI21_Science-Spotlight_ID2675_Vandyck_handout_1.pdf
👍️0
DewDiligence DewDiligence 2 years ago
Link to Leerink webcast:

https://wsw.com/webcast/svbleerink67/enta/2640400
👍️0
oxnous oxnous 2 years ago
ALGS--Bungee Jumping

👍️0
DewDiligence DewDiligence 2 years ago
ALGS -40%/PM on_discontinuation_of_lead HBV candidate for_lack_of_efficacy:

https://finance.yahoo.com/news/aligos-halting-further-development-stops-130000126.html
👍️0
DewDiligence DewDiligence 3 years ago
ALGS—(-16%)—sells 5.06M* shares @$19.00—a 20% discount to Monday’s close:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pricing-83-020800387.html

*Assuming exercise of underwriter’s option.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS—(-11%)—presents EASL HBV lineup:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pipeline-upcoming-120000870.html

Nothing in this PR is especially newsworthy, so I’m not sure why the stock is selling off today. Maybe some investors were expecting some kind of big announcement.
👍️0

Your Recent History

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved